Admedus receives approval for human heart valve implants

Heart surgery product developer Admedus (ASX: AHZ) has received approvals for its first in-human trial at Leuven University Hospital of the company’s proprietary ADAPT single-piece 3D aortic valve. The Belgian surgeon Professor Bart Meuris will conduct the trial of 15 patients who will be followed up six month after receiving the ADAPT implant. Results of…

Lepidico makes progress in lithium chemicals

Lithium chemicals company Lepidico (ASX: LPD) has successfully produced lithium hydroxide monohydrate (LOH) suitable for battery production from its Perth pilot plant operation (pictured). The results were achieved in a batch trial of Lepidico’s proprietary LOH-Max process, with impurity levels comparable to lithium produced using conventional methods. Purities of greater than 56.5 per cent LOH…